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Introduction 
Cognition is a complex mental process, which requires attention, problem-solving, 
decision-making, and working memory. Several brain areas are involved in cognitive 
processes; among others prefrontal cortex (PFC), hippocampus, temporal and parietal 
cortex have prominent roles. Neurological (Alzheimer’s disease – AD, Parkinson’s 
disease – PD) and psychiatric disorders (schizophrenia, depression) are frequently 
accompanied by cognitive deficits.  
Neurodegenerative dementias are usually irreversible and progressive due to the 
decay of neurons. There is a huge unmet medical need for an efficient 
disease-modifying treatment. The drug research has not been able to produce proven 
disease-modifying drugs since the understanding of Alzheimer’s disease 
pathomechanism and suitable disease models are still lacking. Therefore, the research 
and development of procognitive compounds are one of the most challenging areas in 
drug research. Until today, several disappointing clinical trials have disqualified targets 
that were believed to be in the main pathway of the disease, such as amyloid β (Aβ), 
tau, β-side amyloid precursor protein cleaving enzyme (BACE) etc. These negative 
clinical trials draw attention to the inefficient translational power of current animal 
models and call for the improvement of predictive value. 
Fortunately, the highly expanding field of small animal magnetic resonance 
imaging (MRI) seems to be a robust method, which may provide a new approach with 
higher translational power. The functional MRI blood-oxygenation-level dependent 
(BOLD) technique is suitable for the complex testing of brain functions and also the 
circulation. It is an important non-invasive tool in preclinical drug discovery with 
excellent temporal and spatial resolution.  
Rat BOLD pharmacological MRI (phMRI) is gaining popularity in studies aiming 
at the central effect of various pharmacological agents. There are several human phMRI 
studies as well that verify its translational role in neuroscience. The key advantage of 
MRI over other imaging modalities in the neuroscience is its ability to follow changes 
in brain neurobiology after pharmacological, electrical or environmental insult. The 
reconstructed ‘fingerprint’ of the brain activity can characterize the activity and function 
of new psychotherapeutics in preclinical development and study the neurobiology of 
cognition. 
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The cholinergic neurotransmitter system undoubtedly plays a central role in 
cognitive processes. The muscarinergic antagonist scopolamine is a widely used 
memory disturbing amnestic agent in models of cognition by human and preclinical 
studies as well. Its reversible memory impairment property makes it a widely used 
model for the characterization of cognitive enhancers. Beside its negative cognitive 
effect, it also has a strong cerebrovascular action, which is at least partially responsible 
for the negative cognitive effect as was proved by the non-brain penetrating analog 
butylscopolamine.  
 
Objectives 
During my Ph.D. work, I aimed to develop a new, small animal pharmacological 
MRI provocation model, which is applicable for the testing of procognitive agents. The 
major steps of the experimental protocol are summarized in the following points: 
• In the first part of the study we tried to set up a scopolamine-based provocation 
model in our MRI system. First of all, we should find the optimal administration 
route of amnestic agents and procognitive enhancers, furthermore we should 
calculate the optimal length of the pre and post injection periods. After that we 
registered dose-response curves of amnestic agent scopolamine (in the range 
between 1-5 mg/kg doses) to identify its maximal pharmacological effect. 
• In the second part of the study, we were to test the most often prescribed 
procognitive agents (donepezil, piracetam and vinpocetine) against AD in our 
scopolamine-based provocation model.  
• Furthermore, we aimed to test two cognitive enhancer candidates (EVP-6124, 
PNU-120596) which are still in developing phase. In this case, we expected 
improving cognitive functions and consequently increasing BOLD signals in 
cognition-related brain areas.  
• We had only limited information about the pharmacodynamic and pharmacokinetic 
activities of the newly developed Richter compound, RG2260. We had to register 
its dose-response curve and calculate its minimal effective dose in our 
scopolamine-based provocation model. 
• Based on the similar chemical structures of the two Richter compounds 
(vinpocetine and RG2260), we aimed to compare their efficiencies together in the 
  3
same testing system. We were to determine the doses in both cases which leads to 
similar cognitive improvement.  
• In the following part of the study, we tried to examine the vascular components’ 
contribution to cognitive impairment. The amnestic agent was buscopan, which is 
an antimuscarinic molecule with quaternary structure, therefore it does not cross 
BBB. Assuming the presence of vascular effects in cognitive decline, we expected 
decreasing BOLD signals in cognition-related brain areas.   
• In the next part of the study, we tried to examine the vascular components’ 
contribution to cognitive improvement. The presumed cognitive enhancer was 
neostigmine, which is an acetylcholinesterase inhibitor with quaternary structure, 
therefore it does not cross BBB. In this case, we expected BOLD signal intensity 
increase in cognition-related brain areas. 
• Finally, we wanted to compare the results of phMRI experiments to the results of 
behavioral pharmacological tests (water labyrinth test). This labyrinth test was one 
of the most important parts of the whole experiment series to prove the relevance of 
our phMRI results. In the water labyrinth tests we followed a very similar 
experimental protocol as in fMRI experiments. Therefore, we expected similar 
results as in the case of fMRI studies.  
 
Methods 
fMRI measurement 
Male Wistar rats weighing 240-260 g were used in the in vivo experiments. All the 
procedures carried out on animals had been approved by the local ethical committee and 
are in accordance with the rules and principles of the 86/609/EEC Directive. Rats were 
anaesthetized with isoflurane (Sigma-Aldrich; 5 % induction and then reduced to 
1-1.5 % for maintenance of anesthesia during scanning) administered in compressed air. 
To facilitate drug administration during scanning a cannula line was inserted into the rat 
tail vein. We use a 9.4T 21ASZ Varian MRI system. Radiofrequency (RF) pulses were 
transmitted using an actively RF-decoupled two-channel volume coil. A fix-tuned 
receive-only phased array rat brain coil was placed on the dorsal surface of the rat’s 
head to maximize the signal-to-noise ratio. We made T1-weighted anatomical images 
and T2*-weighted functional images.  
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After 1000 sec (16 min 40 sec) baseline period the amnestic agent (scopolamine 
hydrobromide; scopolamine N-butyl bromide or butylscopolamine – Sigma-Aldrich) 
was administered intravenously (i.v.) at 1 mg/kg dose. The administration was 
performed with an infusion pump controlled by optical signals when the animal was in 
the scanner. Procognitive agents or their vehiculum (Sigma-Aldrich; except vinpocetine 
and RG2260) were applied intraperitoneally (i.p.) as pretreatment 1 hour before 
scopolamine/butylscopolamine. The administration of procognitive agents was 
performed in 1 ml/kg volume in saline (donepezil hydrochloride, piracetam, 
neostigmine bromide) or in 5% Tween 80 containing vehiculum (vinpocetine, 
EVP-6124, PNU-120596, RG2260), depending on their solubility. Only one 
measurement was performed with each animal. The exact administration protocol can 
be seen in Table 1. 
Table 1 The administration protocol of cognitive enhancers during fMRI 
measurement 
 Solvent Admin. Doses (mg/kg) 
Donepezil Saline i.p. 1; 4; 10 
Piracetam Saline i.p. 100; 500; 1000 
Vinpocetine 5% Tween 80 i.p. 5 
PNU-120596 5% Tween 80 i.p. 3 
EVP-6124 5% Tween 80 i.p. 1 
Neostigmine Saline i.p. 0.01; 0.03, 0.1; 0.3 
RG2260 5% Tween 80 i.p. 0.01; 0.1; 0.625; 1.25; 2.5; 5; 10 
 
The analysis and the visualization of the data were performed using a custom-made 
Matlab (The Mathworks, Natick, MA, USA) script. Movement was checked, and 
measurements with a higher than one voxel movement were rejected. For statistical 
evaluation t-maps and region of interest (ROI) analysis were also performed according 
to the Rat Brain Atlas of Paxinos and Watson. The t-test was corrected by the 
Benjamini and Hochberg false discovery rate (FDR) method. Statistical significance of 
drug effects was calculated using parametric one-way ANOVA and post-hoc Fisher test 
(Statistica 8.0, StatSoft, USA, Tulsa). Random effect analysis was not considered 
necessary because the animals formed a homogeneous group. 
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Water labyrinth test 
In the water labyrinth task, male Wistar rats (n = 10 per group) had to maneuver 
through three choice points of a labyrinth system in order to reach a platform that 
allowed them to escape from the water. The rats were habituated to the test 
environment, the platform and the labyrinth. The number of directional turning errors 
committed at all the three choice points was measured as a variable reflecting learning 
performance.  
Thirty minutes before the start of the first daily trial, 3 mg/kg (2 ml/kg) i.p. 
scopolamine hydrobromide or buscopan (Sigma-Aldrich) was injected as an amnestic 
agent. Procognitive agents (Sigma-Aldrich; except vinpocetine and RG2260) were 
administered p.o. in 5 ml/kg volume in distilled water (piracetam), in Tween 80 
containing vehiculum (donepezil hydrochloride, EVP-6124, neostigmine bromide, and 
RG2260) or polyethylene glycol (PEG) 400 (PNU-120596) according to their solubility. 
For p.o. vinpocetine administration ascorbic acid solution was used, as the ideal 
vehiculum based on several previous animal studies. The test drugs or their vehiculum 
were administered orally (5 ml/kg) 1 hour before the first swimming except for 
donepezil and EVP-6124, which were given just before the amnestic agent treatment. 
The reversible cholinesterase inhibitor neostigmine and the newly developed 
vinpocetine analog RG2260 were administered intraperitoneally, 30 min prior to the 
first daily swim, likely donepezil and EVP-6124. Each study included a solvent control 
group, a memory impaired group (induced by 3 mg/kg dose of scopolamine or 
buscopan), and one or two impaired groups treated with the test drug. The exact 
administration protocol can be read in Table 2.  
  6
Table 2 The administration protocol of cognitive enhancers during 
behavioral pharmacological measurement 
 Solvent Admin. Dose (mg/kg) 
Donepezil 5 % Tween 80 p.o. 0.25; 0.5; 1; 4; 
Piracetam Distilled water p.o. 500; 750; 1000 
Vinpocetine Ascorbic acid p.o. 5; 7.5; 10 
PNU-120596 PEG 400 p.o. 3; 10 
EVP-6124 5 % Tween 80 p.o. 0.3; 1; 3 
Neostigmine 5 % Tween 80 i.p. 0.3 
RG2260 5 % Tween 80 i.p. 0.625; 1.25; 2.5; 5; 10; 20 
 
Statistical comparisons between parameters of each group were carried out by 
three-way repeated measures ANOVA (Statistica 8.0, StatSoft, USA, Tulsa) using 
'groups' as the independent between groups factor and 'days' and 'trials' as the repeated 
measures factors. Post-hoc comparisons (Duncan-test) were performed in the case of a 
significant between-groups effect or group interaction. The percent reversal by the 
compounds of the amnesia was calculated from the group-means of pooled errors for all 
the trials in the training days using the formula: 
 
100
control of N - amnestic of N
compound of N - amnestic of N%
errerr
errerr x=
 
 
where Nerr means the number of errors. 
 
Results 
fMRI measurement 
In the first part of the study, the effect of scopolamine was tested on the BOLD 
response. It significantly (n=85, p<0.001) decreased the BOLD signal in the prefrontal 
cortex at 1 mg/kg dose but it had no visible effect in other brain regions (Figure 1). The 
effect of scopolamine was not dose-dependent in the dose range 1-5 mg/kg. 
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Figure 1 Effect of scopolamine on BOLD response in the rat brain after 
vehiculum pretreatment. 
 
We tested the butyl analog of scopolamine, buscopan as well. It contains 
quaternary nitrogen, so it cannot enter into the central nervous system (CNS). 
Surprisingly, buscopan at 1 mg/kg intravenous dose caused a marked (n=7, p<0.05) 
negative BOLD response in the prefrontal cortex (PFC) while other brain areas 
remained essentially unchanged. The effect of butylscopolamine was highly similar to 
that of scopolamine; it showed an identical inhibitory pattern and BOLD signal 
reduction at 1 mg/kg dose. 
In the second part of the study the effects of procognitive compounds – 
administered alone – were tested.  
Donepezil had no visible effect at 1 mg/kg i.p. dose. At 4 mg/kg dose, a 
non-significant weak changes were noticed 10-15 minutes after drug administration in 
the cortex and hippocampus. At 10 mg/kg, it caused some short and weak increase of 
BOLD response in most brain areas followed by a long descent. In the PFC and septum, 
the initial increase of BOLD response was absent.  
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The direct administration of piracetam caused a dose-dependent, fast and short 
BOLD response increase in the most studied brain areas. Neostigmine (0.1 mg/kg 
dose), similar to the low dose of donepezil, did not evoke any significant changes in the 
BOLD response when administered alone.  
Vinpocetine, EVP-6124, PNU-120596, and RG2260 could not be tested directly 
in aqueous solution because of their poor solubility. 
In scopolamine-based fMRI provocation model, the reversibility of the memory 
disturbing effect of scopolamine was tested by procognitive compounds. The effect of 
donepezil, piracetam, and neostigmine were compared to that of saline solution used as 
solvent. Vinpocetine, EVP-6124, PNU-120596, and RG2260 were dissolved in 5% 
Tween 80 containing solution; therefore, their effects were compared to that of 5% 
Tween 80 containing saline. The Tween 80 agent was not inert in this model; it 
increased significantly the effect of the amnestic agent (ANOVA, post-hoc Fisher test, 
p<0.05), which points out the importance of adequate control in this very sensitive 
approach.  
 Piracetam was not effective at doses of 100 (n=5) and 500 mg/kg (n=6) against 
scopolamine-induced BOLD response decrease, but at 1000 mg/kg dose (n=5) a clear 
trend was seen. It enhanced the detected BOLD response but this reversal was too small 
to distinguish from the noise (Figure 2). 
The effect of donepezil at 1 mg/kg dose (n=6) was not different from that of the 
control but at higher dose (4 mg/kg, n=11, p<0.01) significantly reduced the inhibitory 
effect of scopolamine. Donepezil at 10 mg/kg dose (n=3) provoked several side effects, 
such as tremor and seizures, therefore, the experiment was discontinued after testing 
three animals (Figure 2). 
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Figure 2 Effects of piracetam and donepezil pretreatment on scopolamine 
evoked BOLD response changes in the prefrontal cortex. Piracetam was 
administered at 100, 500 and 1000 mg/kg intraperitoneally. Donepezil was injected at 1, 
4, and 10 mg/kg intraperitoneally. Scopolamine was tested at 1 mg/kg intravenously. 
(ANOVA, Fisher post-hoc test; *p<0.05; **p<0.01) 
 
Vinpocetine (5 mg/kg, n=5, p<0.05), EVP-6124 (1 mg/kg, n=10, p<0.05) and 
PNU-120596 (3 mg/kg, n=6, p<0.01) significantly inhibited the effect of scopolamine 
in the indicated doses (Figure 3). 
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Figure 3 Effects of vinpocetine, EVP-6124, and PNU-120596 pretreatment on 
scopolamine evoked BOLD response changes in prefrontal cortex. Vinpocetine was 
administered at 5 mg/kg intraperitoneally. EVP-6124 was injected at 1 mg/kg 
intraperitoneally. PNU-120596 was tested at 3 mg/kg intraperitoneally. Scopolamine 
was injected at 1 mg/kg intravenously. (ANOVA, Fisher post-hoc test; *p<0.05; 
**p<0.01) 
 
The newly developed RG2260 agent was effective in BOLD fMRI study against 
scopolamine-induced BOLD response decline in the prefrontal cortex in rats. It was 
formulated and administered in Tween 80 suspension. A dose response curve was 
generated by RG2260 to determine the minimal effective dose (MED). Stable drug 
effect was seen at 0.1 mg/kg dose (n=6) but statistically significant difference was only 
seen at 1.25 (n=6, p<0.05) and 5 mg/kg (n=5, p<0.01) dose. After one hour pretreatment 
RG2260 at 10 mg/kg i.p. was able to prevent the inhibitory effect of scopolamine in rat 
PFC and showed marginally significant result (n=6, p=0.053). The efficacy of the newly 
reported compound (RG2260) seems to be surprisingly similar to that of the reference 
compound vinpocetine. The main difference between these two nootropics is their 
effective doses. Vinpocetine shows significant (n=5, p<0.05) inhibitory effect against 
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scopolamine-induced BOLD response at 5 mg/kg dose while RG2260 is effective (n=6, 
p<0.05) in a much lower dose range (Figure 4). 
 
Figure 4 Effects of vinpocetine and RG2260 pretreatment on scopolamine 
evoked BOLD response changes in the prefrontal cortex. The efficacy of the new 
nootropic RG2260 compound was similar to that of vinpocetine, but it was effective in 
a lower dose range. Vinpocetine was administered at 5 mg/kg intraperitoneally. RG2260 
was injected at 1.25 mg/kg intraperitoneally. Scopolamine was administered at 1 mg/kg 
intravenously. (ANOVA, Fisher post-hoc test; *p<0.05) 
 
The peripherally acting cholinesterase inhibitor neostigmine was tested in 
scopolamine and in buscopan model as well. Pretreatment with 0.1 mg/kg 
intraperitoneal dose had statistically significant (n=5, p<0.05) effect on the BOLD 
response evoked by scopolamine in the PFC. It caused similar, somewhat lower BOLD 
signal changes in comparison to donepezil at 4 mg/kg dose (n=6). Neostigmine at 
0.1 mg/kg dose was able to fully reverse (n=7, p<0.001) the negative BOLD effect of 
buscopan, like donepezil at 4 mg/kg dose (n=4, p<0.001). With both provoking agents 
statistically significant BOLD signal increases were detected when counteracted with 
either neostigmine or donepezil. Interestingly, with scopolamine provocation significant 
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(p<0.05) difference was found between the effect of neostigmine and donepezil 
(Figure 5). 
 
Figure 5 Effects of saline, scopolamine and butylscopolamine (buscopan) on 
BOLD response in the rat brain after saline pretreatment, and prevention of the 
effect of scopolamine and butylscopolamine by neostigmine or donepezil 
pretreatment. Scopolamine (Scop) was administered at 1 mg/kg intravenously. 
Butylscopolamine (Busc) was tested at 1 mg/kg intravenously. Neostigmine (Neost) 
was injected at 0.1 mg/kg intraperitoneally. Donepezil (Donep) was administered at 
4 mg/kg intraperitoneally. *p<0.05, ***p<0.005 from saline; #p<0.05, ###p<0.005 
from scopolamine; ^^^p<0.005 from the butylscopolamine. The arrow means the 
significant difference between the reversal effect of neostigmine and donepezil against 
scopolamine p<0.05 (ANOVA, Fisher post-hoc test). 
 
Water labyrinth test 
Scopolamine (3 mg/kg i.p.) had significant inhibitory effect on the learning 
performance of the animals. It disrupted the normal learning process of rats, resulting in 
a significant increase in the number of errors (Figure 6).  
Piracetam at high doses (750 and 1000 mg/kg, p<0.01) significantly inhibited the 
amnesic effect of scopolamine while the 500 mg/kg dose was inactive (Figure 6). 
  13
 
Figure 6 Effects of piracetam on the learning deficit induced by scopolamine 
in water labyrinth test. Piracetam was adminstered at 750 mg/kg per os. Scopolamine 
was injected at 3 mg/kg intraperitoneally. +p<0.05, ++p<0.01, +++p<0.001 vs. control 
group; *p<0.05, **p<0.01, ***p<0.001 vs. scopolamine-treated group (ANOVA, 
post-hoc Duncan test) 
 
Vinpocetine proved to be effective at doses of 7.5 (p<0.05) and 10 mg/kg 
(p<0.001) in water labyrinth test.  
The inhibitors of acetylcholinesterase appeared to be effective in a much lower 
dose range than other tested agents. Donepezil in a dose range of 0.25-4 mg/kg 
significantly (p<0.01) and dose-dependently improved the learning deficit induced by 
scopolamine. The lowest tested dose (0.25 mg/kg) approximated the minimal effective 
dose of the compound and caused 50 % reversal. At 0.5, 1, and 4 mg/kg dose produced 
63.5 %, 82 %, 71.2 % reversal respectively.  
Neostigmine at 0.3 mg/kg dose also caused a highly significant (p<0.01) and 
considerable (76.8 %) reversal.  
The nicotinic alpha 7 receptor orthosteric agonist EVP-6124 compound at 0.3, 1, 
and 3 mg/kg dose significantly (p<0.05) alleviated the scopolamine-induced learning 
deficit. While PNU-120596, an alpha 7 nicotinic positive allosteric modulator (PAM) 
showed moderate, non-significant improving effect.  
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The newly developed RG2260 was effective in the water labyrinth test against 
scopolamine-induced memory impairment in rats. This compound restored the impaired 
cognitive performance in the dose range of 0.625-20 mg/kg i.p. with a U-shaped 
dose-response pattern. The dose of 0.625 mg/kg was inactive (0.00 % reversal); at 
1.25 mg/kg dose significant improving effect was registered (p<0.05; 44.2 % reversal); 
the maximal effect (p<0.001; 100 % reversal) was obtained at 5 mg/kg dose.  
Butylscopolamine showed a dose-dependent effect; it caused significant (p<0.05) 
impairment in the learning performance at 3 mg/kg dose, which was reversible by 
0.3 mg/kg of neostigmine (p<0.05). 
 
Conclusions 
During my Ph.D work I successfully developed a small animal scopolamine-based 
provocation phMRI model in a team work with my collegues, which model is 
characterized by high translational power and excellent spatial and temporal resolution. 
The developed model was tested with several cognitive enhancers (donepezil, 
piracetam, vinpocetine, neostigmine, EVP-6124, PNU-120596, and RG2260). 
• First, we set up a small animal scopolamine-based provocation MRI system. The 
most effective and successfull protocol was when the administration of 
procognitive agents happened i.p. one hour before the injection of amnestic agent. 
In this case, we could exclude the noising factor of injection procedure and the 
significant pharmacodynamic effect of the applied detergent (Tween 80) from the 
system. The optimal length of the pre-injection baseline was found 1000 sec. After 
this period, the amnestic agent was administered in a saline-based solution via i.v. 
injection to achieve immediately forming effect. The optimal length of a complete 
phMRI experiment was 3000 sec.  
• We tested the amnestic agent scopolamine in various doses. It significantly reduced 
the detected BOLD signal intensity at 1 mg/kg dose in the area of PFC, while other 
brain areas remained intact. The effect of scopolamine was not dose-dependent in 
the dose range 1-5 mg/kg. Maximal pharmacological effect could be seen at 
1 mg/kg dose already. 
• In the second part of the study, we tested commercially available procognitive 
agents. Piracetam, donepezil and the RG compound vinpocetine produced 
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increasing BOLD signal in the PFC of scopolamine-treated animals as we 
previously expected. Significant BOLD signal changes were detected only at 4 and 
10 mg/kg doses of donepezil and at 5 mg/kg of vinpocetine.   
• The next tested alpha 7 selective nicotinerg agents (EVP-6124 and PNU-120596) 
were effective in our phMRI model. Both agents significantly increased the 
registered BOLD signal in cognition-related brain areas as we supposed. 
• We tested the newly developed Richter compound, RG2260 in our model system. 
After the dose-response curve registration in a dose range of 0.01-10 mg/kg, we 
determined the minimal effective dose of RG2260 at 1.25 mg/kg. Significant 
BOLD response increase was detected only at 1.25 and 5 mg/kg doses in PFC.  
• The comparative measurement of vinpocetine at 5 mg/kg and RG2260 at 
1.25 mg/kg dose showed similar results. The detected BOLD signal changes were 
almost the same in both cases but the effective dose of RG2260 agent could be 
detected in a much lower dose range compare to the MED of vinpocetine.  
• Assuming the presence of vascular effects in cognitive decline, it was important to 
test the butyl analogue of scopolamine, buscopan in our phMRI model as 
well.  Surprisingly, it caused a similar marked negative BOLD effect at 1 mg/kg 
dose in the PFC as scopolamine while other brain areas remained intact. Its central 
effect was totally unexpected based on the fact that buscopan cannot penetrate 
through the BBB. 
• Based on the presence of vascular effects in cognitive decline, we presumed similar 
mechanisms in the background of cognitive improvement. In this case, the 
peripherially acting testing agent was neostigmine. It could fully reverse at 
0.1 mg/kg dose the scopolamine and the buscopan-evoked negative BOLD signal 
changes in the PFC. Based on these results, we successfully proved the presence 
and the central role of vascular effects in cognition-related processes. 
• Finally, we compared the results of our phMRI studies to the outcomes of 
behavioral pharmacological tests to prove the relevance of our phMRI results. In 
water labyrinth tests the amnestic agents (scopolamine and buscopan) singificantly 
increased the number of errors by rats, while all of the tested procognitive agents 
showed reduced number of directional turning errors in this scopolamine-based 
provocation model.   
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• Consequently, water labyrinth tests successfully proved the relevance of our phMRI 
results. The outcomes of the two above-mentioned methods were in good 
correspondence with each other. 
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